Insider trade

CEO sold ~$793K of IDXX shares in the open market

Traded Feb 26, 2026 · Filed Mar 2, 2026

Idexx LaboratoriesIDXX

~$793K
Reported value · 1,200 sh @ $661.0976: 87K
Holds after · shares reported: -21.6%
stock since the trade · S&P 500 +10.8%, $660.71 → $517.75 on Oct 1

Why it stands out

The boss of Idexx Laboratories sold $793K of Idexx Laboratories shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 26, 2026
Reporting period: Not applicable
Filed with the SEC: Mar 2, 2026

CEO$500K–$1M

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$793,317

Shares × reported transaction price

Timing vs results

24 days after results of Feb 2, 2026, 68 days before results of May 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $660.71 on Feb 26, 2026, 83% above its 52-week low and 14% below its high, after a 7% drop over the previous 30 trading days

52-week range $361.04 (Apr 8, 2025) to $766.68 (Nov 25, 2025), 74% of the way up, from 251 adjusted closes. 30 trading days earlier: $714.04 on Jan 13, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After it was reported

After	Stock	S&P 500	Difference
7 days	-5.8%	-0.5%	-5.3%
30 days	-10.4%	-3.6%	-6.8%
90 days	-10.8%	+11.5%	-22.3%
180 days	-12.4%	+12.8%	-25.2%

Past results only. Not a forecast.

Source receipt

Record ID: 0000874716-26-000043
Filed / recorded: Mar 2, 2026, 10:00 PM UTC
Added to OQRO: Oct 2, 2026, 12:28 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: IDEXX LABORATORIES INC /DE
Issuer CIK: 874716
Ticker: IDXX
Reporting person: Jonathan Jay Mazelsky
Relationship: Director, Officer
Officer title: President and CEO
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Feb 26, 2026
Transaction code: S
Shares / units: 1,200
Price per share: $661.0976
Acquired / disposed: Disposed (D)
Shares owned after: 87,195.302
Ownership form: Direct
Amendment: No

Footnotes from the filing

Represents the weighted average price of the shares sold ranging from a low of $660.59 to a high of $661.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Around the same time

7mo ago

197Shares · @ $505.53

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record

7mo ago

197Derivative units

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record

Officer sold7mo ago

~$1.12MReported value · 1,758 sh @ $634.5718

Idexx Laboratories's Executive Vice President sold $1.12M of Idexx Laboratories shares. Nobody planned it ahead of time.

Why it stands out Official record